Get the Stockscreener App
19.64
7.31%
-1.55
After Hours:
20.497
0.857
+4.36%
Overview
News
Price History
Option Chain
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is currently priced at $19.64, with a 24-hour trading volume of 1.31M.
It has seen a -7.31% decreased in the last 24 hours and a -10.69% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $21.30 pivot point. If it approaches the $19.50 support level, significant changes may occur.
Cassava Sciences Inc Stock (SAVA) Financials Data
Cassava Sciences Inc (SAVA) Net Income 2024
SAVA net income (TTM) was -$97.22 million for the quarter ending December 31, 2023, a -27.50% decrease year-over-year.
Cassava Sciences Inc (SAVA) Cash Flow 2024
SAVA recorded a free cash flow (TTM) of -$82.44 million for the quarter ending December 31, 2023, a -2.76% decrease year-over-year.
Cassava Sciences Inc (SAVA) Earnings per Share 2024
SAVA earnings per share (TTM) was -$2.32 for the quarter ending December 31, 2023, a -22.11% decline year-over-year.
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ROBERTSON SANFORD | Director |
Aug 23 '23 |
Buy |
17.45 |
30,000 |
523,500 |
886,851 |
| Barry Richard | Director |
Aug 22 '23 |
Buy |
16.65 |
16,571 |
275,907 |
293,477 |
| Barry Richard | Director |
Aug 21 '23 |
Buy |
16.80 |
1,906 |
32,021 |
276,906 |
| SCANNON PATRICK J MD PHD | Director |
Jun 12 '23 |
Option Exercise |
0.95 |
1,000 |
950 |
1,000 |
| BARBIER REMI | President and CEO |
May 24 '23 |
Option Exercise |
16.87 |
71,428 |
1,204,990 |
782,002 |
| BARBIER REMI | President and CEO |
May 24 '23 |
Option Exercise |
16.87 |
14,285 |
240,988 |
390,397 |
| ROBERTSON SANFORD | Director |
May 10 '23 |
Option Exercise |
17.79 |
9,284 |
165,170 |
856,851 |
| GUSSIN ROBERT Z | Director |
May 01 '23 |
Option Exercise |
17.79 |
9,284 |
165,170 |
17,694 |
Cassava Sciences Inc Stock (SAVA) Latest News
Redemption Date Announced for Warrants
GlobeNewswire Inc.
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
GlobeNewswire Inc.
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
GlobeNewswire Inc.
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
GlobeNewswire Inc.
Brian's Big Idea on Low Priced Stocks
Zacks Investment Research
About Cassava Sciences Inc
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
COMPANY PROFILE
NameCassava Sciences Inc
SectorHealthcare (1203)
IndustryBiotechnology (691)
Web
Phone512-501-2444
Employee9
SEC filings
Latest SEC Filings
Next earning date2024-04-29
Address7801 North Capital of Texas Highway, Suite 260, Austin, TX, United States (78731)
1.85%
1.31%
Cap:
|
Volume (24h):